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TO THE EDITOR:
Medical decisions must be based on accurate patient 
evaluations and on robust scientific information. The 
objective of clinical guidelines is to produce useful 
recommendations by identifying the most relevant 
scientific information that should be adapted and applied 
(with caution) in individual patients. This is particularly 
true in COPD, a highly complex, heterogeneous disorder. 
The objective of this study was to evaluate how the 
questionnaires used in symptom evaluation and the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
ABCD assessment tool can affect COPD classification.
This was a cross-sectional study conducted at the 
Outpatient Pulmonary Clinic of the Hospital da Senhora 
da Oliveira, in the city of Guimarães, Portugal. We 
included consecutive patients over 40 years of age who 
had been diagnosed with COPD according to the GOLD 
criteria(1) and in whom the disease was stable. The study 
was approved by the Research Ethics Committees of the 
Hospital da Senhora da Oliveira and of Minho University, 
in the city of Braga, Portugal, as well as by the Portuguese 
Data Protection Authority. All participating patients gave 
written informed consent. We followed the Strengthening 
the Reporting of Observational Studies in Epidemiology 
guidelines.(2)
We applied a questionnaire designed to collect 
demographic and clinical data. Symptoms were evaluated 
with the COPD Assessment Test (CAT) and the modified 
Medical Research Council (mMRC) scale (for dyspnea). 
The number of episodes of acute exacerbation of COPD 
(AECOPD) in the last year was evaluated. We defined 
AECOPD in accordance with the GOLD criteria: as an acute 
worsening of respiratory symptoms that results in the need 
for additional treatment, as well as prompting an unplanned 
medical visit. All participants underwent pulmonary 
function tests in accordance with the recommendations 
of the American Thoracic Society and the European 
Respiratory Society,(3,4) and the results were referenced 
by using the Global Lung Function Initiative predictive 
equations.(5) Statistical analyses were then performed.
We studied a total of 303 outpatients with COPD. The 
main demographic, clinical, and functional characteristics 
of the patients are shown in Table 1. Only 207 patients 
(68.3%) completed the CAT and mMRC questionnaires. 
Applying the proposed GOLD cut-off points for degree 
of dyspnea (mMRC grade) or level of symptom severity 
that requires regular treatment (CAT score), we found 
discordance between the two measures in 47 (22.7%) 
of the 207 patients: 32 (15.5%) were categorized as 
group A and B; and 15 (7.2%) were categorized as group 
C and D. In 38 of those patients, the CAT score was ≥ 
10 and the mMRC grade was < 2, whereas the other 9 
patients presented an mMRC grade ≥ 2 and a CAT score 
< 10. The distribution of patients and the mean FEV1 (% 
of predicted) in each GOLD group, for the two different 
(2016 and 2017) versions of the GOLD guidelines are 
also presented in Table 1. When we applied the 2017 
GOLD criteria, 74 patients (24.4%) were moved from a 
higher severity group to a lower severity group.
In the present study, there was significant discordance 
between the CAT scores and mMRC grades, showing 
that the impact of COPD goes beyond just dyspnea. 
Therefore, in the 96 patients who did not complete 
the CAT, the symptomatic impact might have been 
undervalued and the proposed treatment might have been 
significantly different than what they really needed. These 
observations are consistent with those of other studies. (2) 
In a study conducted in Spain, the 2011 revision of the 
GOLD guidelines, which leaves the choice of method 
for determining the symptomatic impact (mMRC scale 
or CAT) up to the physician, was evaluated in terms 
of the comparison between the two measures.(6) The 
authors found that the classification of COPD patients 
varied depending on the measure employed, more than 
25% of patients being classified in different “horizontal” 
categories, with different proposed treatments.
The GOLD ABCD assessment tool is currently used in 
order to guide pharmacological treatment. We observed 
discordance between the 2016 and 2017 revisions of the 
GOLD guidelines in 24.4% of the patients in our sample. 
Many of them, previously classified as belonging in group 
C or D, were reclassified as belonging in group A or B, 
for which the proposed pharmacological treatment is 
significantly different. Our data are corroborated by those 
of previous studies. One recent study compared the 2011 
and 2017 revisions of the GOLD ABCD assessment tool in a 
sample of 1,532 patients with COPD.(7) The authors found 
that approximately 47% of the 1,070 patients who were 
classified in the higher-severity groups when the 2011 
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revision was used were reclassified into lower-severity 
groups, leading to treatment de-escalation, when the 
2017 revision was used. Tudoric et al.(8) compared 
the 2016 and 2017 GOLD criteria, demonstrating 
two “vertical” shifts in the distribution of patients 
with COPD, more than one third of the patients being 
reclassified from group D to group B when the 2017 
criteria were applied.
Medical decisions and pharmacological treatment 
can be significantly different when distinct validated 
tools, such as standardized questionnaires and clinical 
guidelines, are used. The undervaluation of symptoms 
can result in a greater need for rescue medication, lower 
quality of life, or lower exercise capacity. Nevertheless, 
the transition from the 2016 to the 2017 revision of 
the GOLD ABCD assessment tool would be expected 
to have a significant effect on therapeutic strategies. 
The worsening of the prognosis in groups A and B, due 
to the higher mean airflow limitation, is likely to make 
any acute exacerbation more serious. For example, 
the discontinuation of inhaled corticosteroids can be 
harmful in some of these patients.
Standardized questionnaires, such as the CAT and 
mMRC, should be used in concert, and the results 
should be integrated into a detailed clinical history. 
The changes in the classification of COPD severity in 
the 2017 revision of the GOLD ABCD assessment tool 
must be applied with caution to avoid undertreatment.
Table 1. Demographic, clinical, and functional characteristics of patients with COPD, together with a comparison 
between the 2016 and 2017 Global Initiative for Chronic Obstructive Lung Disease criteria in terms of the distribution 
of patients and mean FEV1.
a
Characteristic (N = 303)
Male gender 241 (79.5)
Age, years 67.5 ± 10.2
Age ≥ 65 years 186 (61.4)
≤ 3 years of schooling 89 (29.4)
Monthly income < €530 197 (65.7)
Smoking history, pack-years 49.3 ± 32.4
mMRC scale grade ≥ 2 185 (61.1)
CAT score ≥ 10 152 (72.4)
≥ 2 episodes of AECOPD in the last year 115 (38.0)
Post-bronchodilator FEV1, % of predicted 53.2 ± 19.7
GOLD 2016
Group
A 51 (16.8)
B 66 (21.8)
C 23 (6.6)
D 163 (53.8)
FEV1, % of predicted, by group
A 76.17 ± 14.20
B 65.76 ± 12.81
C 47.01 ± 14.98
D 41.78 ± 19.68
GOLD 2017
Group
A 70 (23.1)
B 120 (39.6)
C 7 (2.3)
D 106 (35.0)
FEV1, % of predicted, by group
A 66.67 ± 20.07
B 53.61 ± 17.45
C 59.20 ± 21.75
D 43.40 ± 16.02
aValues expressed as mean ± SD or as n (%). mMRC: modified Medical Research Council; CAT: COPD Assessment 
Test; AECOPD: acute exacerbation of COPD; and GOLD: Global Initiative for Chronic Obstructive Lung Disease.
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